TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01124630
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
Study: NCT02493894
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo each 8 hours for 24 hours
Study: NCT01992159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT02582359
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
Study: NCT01698138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 transurethral injections, each of 1 ml solution containing NaCl.
Study: NCT02669277
Drug: IVIG prepared by minipool technology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
Study: NCT02669277
Drug: standard IVIG product
Normalized name: standardized senna concentrate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: to compare efficacy and safety with the minipool IVIG
Study: NCT06335901
Drug: Drug:Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary Intervention
Study: NCT01902524
Drug: Fentanyl-TTS
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
Study: NCT00464243
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00979238
Drug: scAAV2/8-LP1-hFIXco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
Study: NCT02614469
Drug: Inosine
Normalized name: Inosine
DrugBank: Inosine (DB04335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inosine, 1000 mg
Study: NCT02339428
Drug: diclophenac sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given 100mg p.o. diclophenac sodium tablets
Study: NCT02339428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive pill manufactured to mimic diclofenac tablet
Study: NCT00081835
Drug: NP-016 Vaccine Immune Globulin (IV-VIG)
Normalized name: human vaccinia immune globulin Injection [CNJ-016]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02762851
Drug: inactivated trivalent influenza vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml dose injected intramuscularly
Study: NCT02296047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological saline
Study: NCT04529499
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to the placebo + supportive care group in a 1:1 ratio
Study: NCT02518503
Drug: Rosuvastatin (≥10 mg)
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT02518503
Drug: Simvastatin (≥40 mg)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT02518503
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT02518503
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT02518503
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT02518503
Drug: Rosuvastatin (<10mg)
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for \<10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT02518503
Drug: Simvastatin (<40 mg)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-\<365 days, or 366-730 days).
Study: NCT03800472
Drug: GLPG3312 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
Study: NCT03800472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT03800472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo optimized tablets
Study: NCT00812487
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 injections of insulin/day
Study: NCT00025441
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02153580
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02531126
Drug: RPC1063
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02000622
Drug: Physician's choice chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators will declare one of the following regimens:~* Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days~* Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days
Study: NCT03516903
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
Study: NCT03516903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-LDE (Lipid nanoemulsion)
Study: NCT03516903
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid pill
Study: NCT00758706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing to match AZD1236
Study: NCT04493554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo intranasally
Study: NCT02865642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04339361
Drug: vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal dinoprostone 3 mg will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
Study: NCT04339361
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal placebo will be given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
Study: NCT02740660
Drug: Caffeine 100mg / Albuterol 4mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00719797
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00719797
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02740660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02496676
Drug: Intravenous (IV) magnesium sulfate (MgSO4)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part II, participants will be hospitalized to receive 3 days of IV magnesium sulfate (MgS04).
Study: NCT00812643
Drug: AZD0837
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, dosing through the Loc-I-Gut catheter, single dose
Study: NCT00872625
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00872625
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00048087
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg by mouth daily each day for 4 weeks.
Study: NCT03974516
Drug: Careseng 1370
Normalized name: LANCET,CARESENS 30G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Careseng 1370 should be taken around 1 hour before meal.
Study: NCT02129777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection
Study: NCT03232125
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
Study: NCT01001299
Drug: Drug cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
Study: NCT01001299
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg orally twice daily
Study: NCT00860977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
Study: NCT00141570
Drug: esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04449029
Drug: GSK3228836
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
Study: NCT04449029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
Study: NCT04449029
Drug: Nucleos(t)ide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
Study: NCT01661985
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
Study: NCT01661985
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
Study: NCT01661985
Drug: lymecycline
Normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
Study: NCT01861951
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03668418
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study: NCT03668418
Drug: Lederfolin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study: NCT02982603
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identified to Qinggongshoutao Bolus and placebo identified to Ginkgo biloba
Study: NCT01136278
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules identical to MDMA or clonidine
Study: NCT04672252
Drug: CBD Oral Disintegrating Tablet (ODT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen
Study: NCT00031967
Drug: therapeutic melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02589275
Drug: TNX-102 SL Tablet 2.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNX-102 SL 2.8 mg tablet taken daily at bedtime
Study: NCT02812888
Drug: thionamide treatment for 3 months
Normalized name: Retinoids for cancer treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
Study: NCT02502006
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02502006
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01016158
Drug: Umbilical cord serum eyedrops
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% umbilical cord serum eye drops 3 to 4 times a day
Study: NCT02502006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01315821
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 million units/day for 3 months
Study: NCT01315821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 months
Study: NCT01488344
Drug: triple kinase inhibitor BIBF1120
Normalized name: PROTEIN KINASE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
Study: NCT00701623
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive the application of one of two types of heparin directly on the injured area
Study: NCT04148729
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group Ultrasound guided ESP block will not perform. Postoperative analgesia will provide with 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly.
Study: NCT00881452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single unit dose powder of non-active substance administered 3 times per day for 90 days
Study: NCT00495079
Drug: Marqibo® (vincristine sulfate liposomes injection)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
Study: NCT00393042
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: randomized placebo week during each 4 week period
Study: NCT01376557
Drug: 75 mg LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 75 mg LX4211 once daily
Study: NCT01376557
Drug: 200 mg LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 200 mg LX4211 once daily.
Study: NCT01376557
Drug: 400 mg LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 400 mg LX4211 once daily.
Study: NCT01376557
Drug: 200 mg LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 200 mg LX4211 twice daily.
Study: NCT01376557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo once daily.
Study: NCT02655770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00555139
Drug: GSK561679 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
Study: NCT00555139
Drug: GW876008 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
Study: NCT00555139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
Study: NCT03904043
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: -CAPOX can be given as alternative
Study: NCT00374205
Drug: Artemether-Lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
Study: NCT02885974
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (100 mg daily)
Study: NCT01077752
Drug: parenteral analgesia combining acetaminophen and morphine
Normalized name: morphine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: parenteral analgesia combining acetaminophen and morphine
Study: NCT01242917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo film-coated tablets twice daily for 12 weeks + methotrexate
Study: NCT03095547
Drug: F901318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic assessment AUC 0-tau
Study: NCT03673111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT01987947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two administrations by subcutaneous injection
Study: NCT00068653
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400mg orally two times a day, taken with meals.
Study: NCT03834493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01574742
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
Study: NCT04471792
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate will be used in combination with muscle stretching.
Study: NCT01465074
Drug: Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min chewing, one dose
Study: NCT03747094
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mic/kg fentanyl will be given immediately before the procedure
Study: NCT01894568
Drug: Oral Antihyperglycemic Medications (OAMs)
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03989947
Drug: Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)
Study: NCT03792555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, capsules, once daily by mouth
Study: NCT03706365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02476760
Drug: Insulins
Normalized name: INSULINS AND ANALOGUES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
Study: NCT02476760
Drug: Sulfonylureas
Normalized name: Sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT02476760
Drug: Alpha-glucosidase inhibitors
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT00387231
Drug: Anti-ischemic drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04128787
Drug: AG881 Formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG881 uncoated tablets
Study: NCT04128787
Drug: AG881 Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG881 film-coated tablets
Study: NCT03787563
Drug: Herbal Tea
Normalized name: Senna Oral Powder for Suspension [CORRECTOL HERBAL TEA LAXATIVE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.